SMC accepts Boehringer/Lilly’s Jardiance for CKD within NHS Scotland
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read Moreby Jen Brogan | Jul 9, 2024 | News | 0
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read Moreby Lucy Parsons | Sep 2, 2021 | News | 0
Marketing authorisation covers treatment of heart failure with reduced ejection fraction
Read Moreby Lucy Parsons | Jul 7, 2021 | News | 0
Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
Read Moreby Anna Smith | Mar 23, 2020 | News | 0
The decision follows an FDA panel vote last November recommending against the approval of the drug.
Read Moreby Anna Smith | Mar 17, 2020 | News | 0
The decision follows a Jardiance Fast Track designation which was granted by the FDA in July 2019 for the risk of cardiovascular death.
Read Moreby Anna Smith | Sep 19, 2019 | News | 0
Type II diabetes costs the NHS £8.8 billion a year.
Read Moreby Selina McKee | May 30, 2018 | News | 0
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read Moreby Selina McKee | Apr 17, 2018 | News | 0
Boehringer Ingelheim and Eli Lilly are linking with Oxford University to assess the effect of SGLT2 inhibitor Jardiance on kidney disease and cardiovascular death.
Read Moreby Selina McKee | Mar 7, 2018 | News | 0
Boehringer Ingelheim and Eli Lilly are expanding their clinical trial programme for Jardiance in chronic heart failure (CHF) with two new Phase III studies.
Read Moreby Selina McKee | Dec 5, 2016 | News | 0
In a huge boon for Lilly and Boehringer Ingelheim, US regulators have expanded the scope of diabetes drug Jardiance to include a reduction in the risk of cardiovascular death patients with type II forms of the condition and cardiovascular disease.
Read Moreby Selina McKee | May 25, 2016 | News | 0
Cost regulators for the NHS in England and Wales are backing the use of three monotherapies to treat patients with diabetes type 2: Janssen’s Invokana, AstraZeneca’s Forxiga and Boehringer Ingelheim/Lilly’s Jardiance.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
